NAS10026,990+1.35%S&P7,377+0.31%GOLD$4,075−0.94%BTC$75,835+0.12%VIX25.64−9.01%latest tape · as of 14:00 UTC
The Screen · Financials · Asset Management
Raymond James Financial
RJF · a US exchange · USD · Market cap $30.2B · 19,500 employees
Raymond James Financial, Inc., a diversified financial services company, provides private client group, capital markets, asset management, banking, and other services to individuals, corporations, and municipalities in t…
FAIL · Does not pass the screen
162.81 USD
Price as of 6 Nov 2026Daily close, not a live quote
Screened 2026-11-06 · the tape above runs as of 14:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price162.81 USD at the 6 Nov 2026 close
Our value readUndervalued vs our fair value, as of 6 Nov 2026
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.30, read 2026-11-02
Ethical does not pass the values gate
Price162.81 USD
Fair value205.00
Ethical score10.0/100
Value readUndervaluedas of 6 Nov 2026
Our investment reviews on this name
2026-11-04Read Markdown161.67+0.7% to today Accumulation gives way to Markdown first Markdown read since October
2026-10-26Read Accumulation157.37+3.5% to today ✓Markdown gives way to Accumulation after a 10% slide in 6 weeks
2026-09-11Read Markdown175.47-7.2% to today ✓Markup gives way to Markdown first Markdown read since July
2026-08-11Read Markup180.55-9.8% to today Markdown gives way to Markup after a 19% rise in 6 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Raymond James Financial holds its Markup at $162.81. Consolidating, no directional conviction, held for 56 days.
As held on the ledger · 2026-11-06
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 56 days
Price at the screen
$162.81
Valuation
13.20 trailing · 9.67 forward price to earnings
Values screen
FAIL· score 10.0
Beta
0.95
The Workings
Five Screens, Shown in Full
Does not pass. Business activity screen
Test
Figure
Limit
What it means
Status
Business activity
Excluded
Core business clean
Business activity: Financials sector
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Raymond James Financial does not clear the screen at the business-activity stage. It operates in conventional financial services, which the screen treats as interest-based, so the financial ratios are not the deciding factor here.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when RJF's ethical verdict changes
Today RJF does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 6 Nov 2026: it trades at roughly a 20% discount to our $205.00 fair value, moderate competitive moat, 15.70% revenue growth.
Fair value range in USD, drawn from the 2026-11-06 screen. The gold marker is the market price at the same screen. A 20.6% discount to the base estimate.
Where our models see it going: fair-value estimate $205.00, with a range of $182.88 to $304.79, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Brokers Can Look Cheap Yet Still Fail Us
Picture a steady wealth manager guiding retirees through market swings while quietly tripping an ethical screen on core business lines. That is Raymond James at 168 dollars a share, with analysts clustered around a 179 target and our own fair value at 195. We pass anyway.
Revenue is growing 13 percent and the firm earns a 17 percent return on equity with a moderate moat, yet the ethical failure on business activity rules it out regardless of the 11.9 times forward earnings or 15 percent profit margin. The 16 percent margin of safety to our number changes nothing when the screen is breached.
Risk sits in the ethical breach itself plus any cyclical pressure on asset management fees when markets turn. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
RJF trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-04Markdown · changed$161.67+2.7%Entry 16
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 2.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (14 analysts) rates it buy, with a mean price target of $182.
2026-10-28Accumulation$157.37+0.0%Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (14 analysts) rates it buy, with a mean price target of $184. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Accumulation$157.37+0.0%Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (14 analysts) rates it buy, with a mean price target of $184. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (14 analysts) rates it buy, with a mean price target of $184. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Markdown$157.37+0.0%Entry 12
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (14 analysts) rates it buy, with a mean price target of $184. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Markdown$157.37+0.0%Entry 11
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (14 analysts) rates it buy, with a mean price target of $184. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Markdown$157.37+0.0%Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (14 analysts) rates it buy, with a mean price target of $184. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22Markdown$157.37+0.0%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (14 analysts) rates it buy, with a mean price target of $184. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Markdown$157.37-0.6%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (14 analysts) rates it buy, with a mean price target of $184. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-14Markdown$158.38-1.7%Entry 7
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (14 analysts) rates it buy, with a mean price target of $184.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
